

42. **Auprich M, Chun FKH, Ward JF, et al.** Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging. *European Urology* [Internet]. 1. leden 2011 [citován 1. srpen 2024]; 59(1): 96–105. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S0302283810009620>.
43. **Vlaeminck-Guillem V, Ruffion A, André J, Devonec M, Paparel P.** Urinary Prostate Cancer 3 Test: Toward the Age of Reason? *Urology* [Internet]. 1. únor 2010 [citován 22. září 2024]; 75(2): 447–53. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S0090429509005123>.
44. **Auprich M, Bjartell A, Chun FKH, et al.** Contemporary Role of Prostate Cancer Antigen 3 in the Management of Prostate Cancer. *European Urology* [Internet]. 1. listopad 2011 [citován 22. září 2024]; 60(5): 1045–54. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S0302283811008633>.
45. **Hessels D, Smit FP, Verhaegh GW, et al.** Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. *Clinical Cancer Research*. 2007; 13(17): 5103–8.
46. **Schoenborn JR, Nelson P, Fang M.** Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. *Clin Cancer Res* [Internet]. 1. srpen 2013 [citován 22. září 2024]; 19(15): 4058–66. Dostupné z: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732571/>.
47. **Nilsson J, Skog J, Nordstrand A, et al.** Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. *Br J Cancer* [Internet]. květen 2009 [citován 22. září 2024]; 100(10): 1603–7. Dostupné z: <https://www.nature.com/articles/6605058>.
48. **Tomlins SA, Day JR, Lonigro RJ, et al.** Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. *European Urology* [Internet]. 1. červenec 2016 [citován 22. září 2024]; 70(1): 45–53. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S0302283815003978>.
49. **Tosoian JJ, Singhal U, Davenport MS, et al.** Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. *Urology* [Internet]. 1. červen 2022 [citován 22. září 2024]; 164: 184–90. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S0090429521011626>.
50. **Kohaar I, Chen Y, Banerjee S, et al.** A Urine Exosome Gene Expression Panel Distinguishes between Indolent and Aggressive Prostate Cancers at Biopsy. *The Journal of Urology* [Internet]. únor 2021 [citován 22. září 2024]; Dostupné z: <https://www.auajournals.org/doi/10.1097/JU.0000000000001374>.
51. **Mrcochova H, Hezova R, Stanik M, Slaby O.** Urine microRNAs as potential noninvasive biomarkers in urologic cancers. *Urologic Oncology: Seminars and Original Investigations* [Internet]. 1. leden 2014 [citován 22. září 2024]; 32(1): 41.e1–41.e9. Dostupné z: <https://www.sciencedirect.com/science/article/pii/S107814391300197X>.
52. **Ahumada-Tamayo S, Saavedra-Briones D, Cantellano-Orozco M, et al.** MicroRNA determination in urine for prostate cancer detection in Mexican patients at the Hospital General Dr. Manuel Gea González. *Rev Mex Urol* [Internet]. 2011 [citován 22. září 2024]; 71(4): 213–7. Dostupné z: <https://www.medigraphic.com/cgi-bin/new/resumenl.cgi?IDREVISTA=85 & IDARTICULO=31413 & IDPUBLICACION=3401>.
53. **Bryant RJ, Pawlowski T, Catto JWF, et al.** Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer* [Internet]. 14. únor 2012 [citován 1. srpen 2024]; 106(4): 768–74. Dostupné z: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322952/>.
54. **Ferro M, Rocco B, Maggi M, et al.** Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification. *Expert Review of Molecular Diagnostics* [Internet]. 2. prosinec 2023 [citován 22. září 2024]; 23(12): 1061–70. Dostupné z: <https://doi.org/10.1080/14737159.2023.2277366>.
55. **Prostate Cancer – Uroweb [Internet].** [citován 22. září 2024]. Dostupné z: <https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation>.